Redmile Group’s Edwards Lifesciences EW Stock Holding History

Redmile Group’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-654,000	Closed	-$25.8M	–	70
2017 Q2	$25.8M	Buy	+654,000	New	+$23.9M	1.57%	23

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Redmile Group's EW Position: Q3 2017 in Review

Redmile Group sold out of Edwards Lifesciences (EW) in Q3 2017, closing a stake of 654,000 shares — an estimated $25.8M sold.

Redmile Group first reported a position in EW in Q2 2017 and held it in 1 quarter. The position peaked at $25.8M in Q2 2017. 739 funds tracked by Wall St. Rank hold EW as of Q3 2017.

Redmile Group reported no remaining Edwards Lifesciences position as of Q3 2017 after selling out during the quarter.
Redmile Group sold 654,000 Edwards Lifesciences shares in Q3 2017, an estimated $25.8M.
Redmile Group first reported a position in Edwards Lifesciences in Q2 2017 and held it in 1 quarter.
Redmile Group's Edwards Lifesciences position peaked at $25.8M in Q2 2017.
739 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2017.

Based on Redmile Group's 13F filing for Q3 2017, filed 14 Nov 2017.